EUVIMEDEUVIMED entdecken
Systematische ÜbersichtLeitlinie

Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update

Nataniel Mandelberg, Tiffany R Hodges, Tony J C Wang, Tresa McGranahan, Jeffrey J Olson, Daniel A Orringer

Journal of Neuro-Oncology · 2025

DOI: 10.1007/s11060-024-04898-7 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Nataniel Mandelberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, NYU Langone Health and NYU Grossman School of Medicine, 530 1st Avenue, Skirball Suite 8R, New York, NY, 10016, USA. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Practice Guidelines as Topic, Evidence-Based Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

QUESTIONS AND RECOMMENDATIONS FROM THE PRIOR VERSION OF THESE GUIDELINES WITHOUT CHANGE: TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected low-grade diffuse glioma. QUESTION: What are the optimal neuropathological techniques to diagnose low-grade diffuse glioma in the adult? RECOMMENDATION: Level I Histopathological analysis of a representative surgical sample of the lesion should be used to provide the diagnosis of low-grade diffuse glioma. Level III Both frozen section and cytopathologic/smear evaluation should be used to aid the intra-operative assessment of low-grade diffuse glioma diagnosis. A resection specimen is preferred over a biopsy specimen, to minimize the potential for sampling error issues. TARGET POPULATION: Patients with histologically-proven WHO grade II diffuse glioma. QUESTION: In adult patients (age ≥ 18 years) with histologically-proven WHO grade II diffuse glioma, is testing for IDH1 mutation (R132H and/or others) warranted? If so, is there a preferred method? RECOMMENDATION: Level II IDH gene mutation assessment, via IDH1 R132H antibody and/or IDH1/2 mutation hotspot sequencing, is highly-specific for low-grade diffuse glioma, and is recommended as an additional test for classification and prognosis. TARGET POPULATION: Patients with histologically-proven WHO grade II diffuse glioma. QUESTION: In adult patients (age ≥ 18 years) with histologically-proven WHO grade II diffuse glioma, is testing for 1p/19q loss warranted? If so, is there a preferred method? RECOMMENDATION: Level III 1p/19q loss-of-heterozygosity testing, by FISH, array-CGH or PCR, is recommended as an additional test in oligodendroglial cases for prognosis and potential treatment planning. TARGET POPULATION: Patients with histologically proven WHO grade II diffuse glioma. QUESTION: In adult patients (age > 18 years) with histologically-proven WHO grade II diffuse glioma, is methyl-guanine methyl-transferase (MGMT) promoter methylation testing warranted? If so, is there a preferred method? RECOMMENDATION: There is insufficient evidence to recommend MGMT promoter methylation testing as a routine for low-grade diffuse gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess the value of this and related markers for this target population. TARGET POPULATION: Patients with histologically-proven WHO grade II diffuse glioma. QUESTION: In adult patients (age ≥ 18 years) with histologically proven WHO grade II diffuse glioma, is Ki-67/MIB1 immunohistochemistry warranted? If so, is there a preferred method to quantitate results? RECOMMENDATION: Level III Ki67/MIB1 immunohistochemistry is recommended as an option for prognostic assessment. NEW RECOMMENDATION: TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected WHO grade II diffuse glioma. QUESTION: Is testing for ATRX mutations helpful for predicting survival and making treatment recommendations? RECOMMENDATION: There is insufficient evidence to recommend ATRX mutation testing as a means of predicting survival or making treatment recommendations. TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected WHO grade II diffuse glioma. QUESTION: Does the addition of intraoperative optical histologic methods provide accuracy beyond the use of conventional histologic methods in diagnosis and management? RECOMMENDATION: There is insufficient evidence at this time to suggest that intraoperative optical histologic methods offer increased diagnostic accuracy when compared to conventional techniques.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsPractice Guidelines as TopicEvidence-Based MedicineNeuropathologyHumansNeoplasm GradingWorld Health OrganizationAdult

Stichwörter der Autor:innen

HistopathologyLow-grade gliomaMolecular Markers

Autor:innen und Institutionen

  • Department of Neurosurgery, NYU Langone Health and NYU Grossman School of Medicine, 530 1st Avenue, Skirball Suite 8R, New York, NY, 10016, USA.
  • Brain and Spine Tumor Center, Laura and Isaac Perlmutter Cancer Center, New York, NY, USA.
  • Department of Neurosurgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
  • Department of Radiation Oncology, Columbia University Medical Center, New York, NY, USA.
  • Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA.
  • Department of Neurological Surgery, Emory University School of Medicine, Atlanta, GA, USA.

Zitieren

APA

Mandelberg, N., Hodges, T. R., Wang, T. J. C., McGranahan, T., Olson, J. J., & Orringer, D. A. (2025). Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04898-7

Vancouver

Mandelberg N, Hodges TR, Wang TJC, McGranahan T, Olson JJ, Orringer DA. Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-024-04898-7

BibTeX
@article{Mandelberg2025,
  author = {Mandelberg, Nataniel and Hodges, Tiffany R and Wang, Tony J C and McGranahan, Tresa and Olson, Jeffrey J and Orringer, Daniel A},
  title = {Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update},
  journal = {Journal of Neuro-Oncology},
  year = {2025},
  doi = {10.1007/s11060-024-04898-7}
}
Kostenlos starten →